Catheter Ablation Versus Antiarrythmic Drugs for Atrial Fibrillation in China

Atrial Fibrillation Therapy: A Multi-Center Clinical Study

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01341353

Enrollment

1800

Registered

2011-04-25

Start date

2011-04-30

Completion date

2015-12-31

Last updated

2011-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Brief summary

The mainstay of treatment for atrial fibrillation remains pharmacological;however,catheter ablation has increasingly been used over the last decades. The relative merits of each strategy have not been extensively studied. Our study was designed to determine if catheter ablation is a feasible option as first-line therapy for treating patients with symptomatic AF.

Interventions

PROCEDUREcatheter ablation

circumferential pulmonary vein isolation complex fractionated atrial electrograms ablation circumferential pulmonary vein isolation combined left atrial roof ablation circumferential pulmonary vein isolation combined left atrial isthmus ablation circumferential pulmonary vein isolation combined left atrial roof and isthmus ablation circumferential pulmonary vein isolation combined complex fractionated atrial electrograms ablation

DRUGDigaoxin,amiodarone,β receptor antagonist, Calcium Antagonists

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* 1 Patients with symptomatic AF recorded by ECG or Holter 2 Age:18-75 years 3 Patients who are willing to enroll in the trial

Exclusion criteria

* 1 Patients accompanied hyperthyroidism 2 Patients with sever liver or renal dysfunction 3 Patients with sever cardiac dysfunction 4 Patients had previous radiofrequency catheter ablation in the LA or Maze surgical procedure 5 Patients with emboli in atrium 6 Pregnant woman

Design outcomes

Primary

Measure	Time frame
Number of participants with all-cause death	3 month
severe blooding complications	3 month
cardio-cerebrovascular complications	3 month
Number of participants with cardiovascular death events	3 month

Secondary

Measure	Time frame
recurrence of atrial arrhythmias (AF, AFL, AT)	3 month
resource utilization and costs	12 month

Countries

China

Contacts

Primary ContactCong xin Huang, doctor

huangcongxin@yahoo.com.cn13907131546

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026